ProKidney Corp. PROK
Set alert
1.30 USD -0.18 -11.90%
At close · Oct 30
1.33 +0.04 +2.70%
After hours · Oct 30, 6:08 PM ET
1.29 Day range 1.46
1.30 52-week range 3.08
- YTD
- -42.19%
- 1 year
- -57.95%
- Open
- 1.41
- Prev close
- 1.47
- Mkt cap
- 516.94M
- Vol
- 1.73M
- Avg vol
- 1.31M
- EPS
- -0.55
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.29
- High
- 1.46
- Forward P/E
- -5.33
- Beta
- 1.79
- Short ratio
- 3.72
- Inst. own
- 30.44%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.68
- 200-d avg
- 1.62
- 1y target
- 5.83
Key statistics
- Market cap
- 800.45M
- Enterprise value
- 1.42B
- Trailing P/E
- 0.00
- Forward P/E
- -5.33
- PEG ratio
- 0.00
- Price / sales
- 1518.88
- Price / book
- 0.00
- EPS (TTM)
- -0.56
- Beta
- 1.79
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 527.00K
- Revenue growth
- 0.00%
- Free cash flow
- -112.58M
- Total cash
- 294.73M
- Total debt
- 4.42M
- Return on equity
- -40.52%
- Shares outstanding
- 134.99M
- Short % of float
- 8.70%
- 50-day average
- 2.68
- 200-day average
- 1.62
Analyst view
Consensus: none
Price target (mean) 5.83 +350.5% upside
Now 1.30
- Target (low)
- 1.00
- Target (mean)
- 5.83
- Target (high)
- 10.00
Ratings (0m) 8 4 buy · 3 hold · 1 sell
- Strong buy0
- Buy4
- Hold3
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate -0.13861.
Financials — quick view
PROK Revenue — quarterly 150.00K
PROK Net income — quarterly -28.42M
PROK EPS — quarterly -0.15
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 15, 2025 | UBS | main | Buy | Buy |
| Jul 14, 2025 | Guggenheim | main | Buy | Buy |
| Jul 9, 2025 | Citigroup | main | Buy | Buy |
| Jun 30, 2025 | B of A Securities | down | Neutral | Underperform |
| Sep 30, 2024 | JP Morgan | init | — | Neutral |
| Sep 10, 2024 | Guggenheim | init | — | Buy |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- prokidney.com
News
- ProKidney Corp. Enters $200 Million At-The-Market Offering Agreement With Jefferies
- Citigroup Maintains Buy on ProKidney, Lowers Price Target to $8
- ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500
- ProKidney Corp. (PROK) Discusses Rilparencel Mechanism and Role in Advanced Chronic Kidney Disease Transcript
- ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update
- ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026
- ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026
- Critical Analysis: Pyxis Oncology (NASDAQ:PYXS) vs. ProKidney (NASDAQ:PROK)
- 20 stocks likely to lose money even if the bull market continues
- ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)
Your note
Sign in to keep a note on PROK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CONTROL EMPRESARIAL DE CAPITALES, S.A. DE C.V. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 21, 2025 | 10,724,100 |
| GIROLAMO TODD C. J.D. | Officer | Conversion of Exercise of derivative security | Jul 30, 2024 | 163,856 |
| LEGORRETA PABLO G | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 2, 2025 | 0 |
| PALIHAPITIYA CHAMATH | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 16, 2023 | 0 |
| PEREIRA BRIAN J G | Director | Conversion of Exercise of derivative security | Feb 3, 2025 | 0 |
| WEBER DARIN J. | Officer | Sale | Jul 7, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 9.14% | 12,341,266 | 33.57M | Jun 29, 2025 |
| Morgan Stanley | 4.44% | 5,987,541 | 16.29M | Jun 29, 2025 |
| Bleichroeder LP | 1.48% | 2,000,000 | 5.44M | Jun 29, 2025 |
| Blackrock Inc. | 1.31% | 1,764,607 | 4.80M | Jun 29, 2025 |
| JPMORGAN CHASE & CO | 1.24% | 1,668,642 | 4.54M | Jun 29, 2025 |
| Vanguard Group Inc | 1.16% | 1,567,868 | 4.26M | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.02% | 1,375,453 | 3.74M | Jun 29, 2025 |
| Brighthouse Funds Trust I-Morgan Stanley Discovery Portfolio | 0.63% | 849,350 | 2.31M | Jun 29, 2025 |
| Morgan Stanley Insight Fund | 0.59% | 795,260 | 2.16M | Jun 29, 2025 |
| MORGAN STANLEY INSTITUTIONAL FUND TRUST-Discovery Portfolio | 0.54% | 733,305 | 1.99M | Jun 29, 2025 |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 0.42% | 571,795 | 1.56M | May 30, 2025 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 0.36% | 492,006 | 1.34M | Jul 30, 2025 |